← Back to articles

health

Health & Medicine

The FDA has approved a new drug that could extend survival for late-stage pancreatic cancer patients, offering potential hope for a disease with historically poor outcomes.

HIGH confidence neutral tone

Coverage (16902 articles)

News-Medical · Jun 23, 2026

IL1RAP-blocking therapy advances to pancreatic cancer clinical trial

Researchers at University of Miami's Sylvester Cancer Center have identified IL1RAP as a key inflammatory control point in pancreatic cancer resistance, advancing toward a clinical trial combining IL1RAP-targeted therapy with chemoimmunotherapy in operable patients.

ADN Radio · Jun 23, 2026

Grupo sanguíneo B vinculado a mayor riesgo de diabetes tipo 2

Un metaanálisis de 51 estudios científicos encontró que personas con grupo sanguíneo B tienen 28% más probabilidades de desarrollar diabetes tipo 2, aunque factores como sedentarismo y sobrepeso siguen siendo más determinantes.

← Previous Page 280 of 705 Next →
Contact Us FAQ